DRRX Durect Corp

Price (delayed)

$1.7

Market cap

$386.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.01

Enterprise value

$354.69M

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic ...

Highlights
Durect's equity has soared by 104% from the previous quarter
The EPS has soared by 92% year-on-year
The net income has soared by 97% YoY but it has contracted by 32% from the previous quarter

Key stats

What are the main financial stats of DRRX
Market
Shares outstanding
227.41M
Market cap
$386.59M
Enterprise value
$354.69M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.73
Price to sales (P/S)
12.52
EV/EBIT
252.99
EV/EBITDA
212.77
EV/Sales
12
Earnings
Revenue
$29.55M
EBIT
$1.4M
EBITDA
$1.67M
Free cash flow
-$36.63M
Per share
EPS
-$0.01
Free cash flow per share
-$0.17
Book value per share
$0.36
Revenue per share
$0.14
TBVPS
$0.51
Balance sheet
Total assets
$116.06M
Total liabilities
$34.33M
Debt
$25.65M
Equity
$81.72M
Working capital
$93.11M
Liquidity
Debt to equity
0.31
Current ratio
8.96
Quick ratio
8.38
Net debt/EBITDA
-19.14
Margins
EBITDA margin
5.6%
Gross margin
98.2%
Net margin
-2.6%
Operating margin
-42.8%
Efficiency
Return on assets
-0.9%
Return on equity
-1.6%
Return on invested capital
2.3%
Return on capital employed
1.3%
Return on sales
4.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DRRX stock price

How has the Durect stock price performed over time
Intraday
1.19%
1 week
-2.86%
1 month
-3.41%
1 year
-24.78%
YTD
-17.87%
QTD
-14.14%

Financial performance

How have Durect's revenue and profit performed over time
Revenue
$29.55M
Gross profit
$29.02M
Operating income
-$12.65M
Net income
-$768,000
Gross margin
98.2%
Net margin
-2.6%
The net income has soared by 97% YoY but it has contracted by 32% from the previous quarter
The net margin has surged by 97% year-on-year but it has declined by 37% since the previous quarter
DRRX's operating margin has soared by 58% YoY but it is down by 2.1% QoQ
The company's operating income rose by 45% YoY

Growth

What is Durect's growth rate over time

Valuation

What is Durect stock price valuation
P/E
N/A
P/B
4.73
P/S
12.52
EV/EBIT
252.99
EV/EBITDA
212.77
EV/Sales
12
The EPS has soared by 92% year-on-year
Durect's equity has soared by 104% from the previous quarter
DRRX's P/B is 67% below its 5-year quarterly average of 14.4 and 51% below its last 4 quarters average of 9.6
The revenue has grown by 31% year-on-year
The price to sales (P/S) is 18% higher than the 5-year quarterly average of 10.6 and 4.3% higher than the last 4 quarters average of 12.0

Efficiency

How efficient is Durect business performance
The ROS has soared by 105% year-on-year but it is down by 15% since the previous quarter
Durect's return on invested capital has surged by 104% YoY but it has decreased by 26% QoQ
Durect's ROE has soared by 99% YoY and by 16% from the previous quarter
Durect's ROA has soared by 97% YoY but it has decreased by 13% from the previous quarter

Dividends

What is DRRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DRRX.

Financial health

How did Durect financials performed over time
The company's quick ratio has surged by 58% QoQ
The total assets has soared by 57% YoY and by 53% from the previous quarter
The debt is 69% smaller than the equity
Durect's equity has soared by 104% from the previous quarter
The debt to equity has dropped by 84% year-on-year and by 52% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.